Tobramycin Via pharma Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

tobramycin via pharma

via pharma, uab - tobramicinas - purškiamasis įkvepiamasis tirpalas - 300 mg/5 ml - tobramycin

Taifun® B Lietuva - lietuvių - Adama

taifun® b

adama - vandens tirpalas - glifosatas - herbicidai

Flebogamma DIF (previously Flebogammadif) Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

flebogamma dif (previously flebogammadif)

instituto grifols s.a. - Žmogaus normalus imunoglobulinas - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - imuninės serumai ir imunoglobulinai, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Legacy® Pro Lietuva - lietuvių - Adama

legacy® pro

adama - koncentruota suspensija - chlorotoluronas + diflufenikanas + pendimetalinas - herbicidai

Alfacalcidol Strides Pharma Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

alfacalcidol strides pharma

strides pharma (cyprus) limited - alfakalcidolis - minkštosios kapsulės - 0,25 µg - alfacalcidol

Alfacalcidol Strides Pharma Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

alfacalcidol strides pharma

strides pharma (cyprus) limited - alfakalcidolis - minkštosios kapsulės - 0,5 µg - alfacalcidol

Alfacalcidol Strides Pharma Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

alfacalcidol strides pharma

strides pharma (cyprus) limited - alfakalcidolis - minkštosios kapsulės - 1 µg - alfacalcidol

Kauliv Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

kauliv

strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - kalcio homeostazė - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Goltix® 700 SC Lietuva - lietuvių - Adama

goltix® 700 sc

adama - koncentruota suspensija - metamitronas - herbicidai

Blincyto Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomabas - prekursorių ląstelių limfoblastinė leukemija-limfoma - antinavikiniai vaistai - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.